TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24300901
Drug: Perceived neighborhood
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perceived neighborhood drug involvement
Study: 22405251
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin plus prednisolone (2 mg/kg per day for 15 days after C-reactive protein normalised)
Study: 22405251
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day)
Study: 18679597
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (Jieze No.1 + Azithromycin)
Study: 16291411
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg QD plus Metformin 500 mg TID (G + M)
Study: 16291411
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg QD plus Metformin 500 mg TID (R + M)
Study: 10424932
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy using tissue plasminogen activator (tPA) at a dose of 0.9 mg/kg body weight.
Study: 10424932
Drug: Streptokinase therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase therapy.
Study: 10424932
Drug: Ancrod therapy
Normalized name: ancrod
DrugBank: Ancrod (DB05099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancrod therapy (STAT study).
Study: 10424932
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (general).
Study: 2112180
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (IV STK)
Study: 2112180
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen (IV TPA)
Study: 1270971
Drug: Ethanol (133.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (133.7 g)
Study: 29173606
Drug: High ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High ticagrelor loading dose (360 mg)
Study: 29173606
Drug: Conventional ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional ticagrelor loading dose (180 mg)
Study: 16495695
Drug: Percutaneous local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous local ablative therapy (PLAT)
Study: 8248660
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (specific types not mentioned)
Study: 31573387
Drug: Insoluble yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insoluble yeast β‐glucan (250 mg, 250 mL/day)
Study: 31573387
Drug: Soluble yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble yeast β‐glucan (250 mg, 250 mL/day)
Study: 22090363
Drug: Oral losmapimod
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral losmapimod 7.5 mg twice daily
Study: 22090363
Drug: Inhaled salmeterol/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol/fluticasone propionate 50 µg/500 µg combination (SFC)
Study: 20384393
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg single oral dose in ESRD patients
Study: 20384393
Drug: Duloxetine 20-60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20-60 mg once or twice daily in phase II/III trials
Study: 18727457
Drug: 7-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day standard triple therapy
Study: 18727457
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy plus L. reuteri
Study: 18727457
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy plus probiotic mixture
Study: 18727457
Drug: 14-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day standard triple therapy plus probiotic mixture
Study: 15999046
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (1 g of methylprednisolone before surgery and 4 mg of dexamethasone every 6 hours for 1 day after surgery)
Study: 10636535
Drug: Tirofiban and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban and unfractionated heparin (n=27)
Study: 10636535
Drug: Tirofiban and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban and unfractionated heparin
Study: 7181738
Drug: Isocaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diet with 400 mg cholesterol and 0.8 polyunsaturated-to-saturated fat ratio
Study: 27495968
Drug: Standard surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgery plus standard voice therapy
Study: 27495968
Drug: Voice Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice Therapy Expulsion
Study: 25847554
Drug: Combination (900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (900mg Black seeds and 1.5g Turmeric/day)
Study: 21443724
Drug: Repetitive rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive rectal painful distention (RRD)
Study: 21443724
Drug: Intravenous CRF
Normalized name: CRF
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CRF (100 µg)
Study: 19234822
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg IV ramosetron
Study: 19234822
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg oral ramosetron
Study: 15738933
Drug: Post-treatment phone
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment phone contact (experimental group)
Study: 12423848
Drug: Water-soluble gel
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble gel lubricant
Study: 1707221
Drug: Metformin (placebo)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (placebo)
Study: 6814470
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (30 mg)
Study: 6814470
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (60 mg)
Study: 6814470
Drug: +/--glaucine phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: +/--glaucine phosphate (60 mg)
Study: 6814470
Drug: +/--glaucine phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: +/--glaucine phosphate (30 mg)
Study: 27392909
Drug: Conventional lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lipid lowering drugs (Group C)
Study: 24721903
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon α (IFNα) treatment
Study: 21068719
Drug: Iomazenil (3.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomazenil (3.7 μg administered intravenously over 10 min)
Study: 18397193
Drug: Functional exercise
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional exercise training (supervised by a physical therapist, three times weekly for 4 months)
Study: 17450980
Drug: 10-week, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week, 3 days/week weight-training treatment
Study: 12488953
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose tolerance test
Study: 12488953
Drug: Islet-cell antibody
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet-cell antibody greater than 20 JDFU
Study: 12488953
Drug: Insulin autoantibodies
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin autoantibodies
Study: 9690691
Drug: Ipsapirone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 50 mg once daily
Study: 9690691
Drug: Ipsapirone 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 30 mg once daily
Study: 8006249
Drug: Angina-guided medical
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angina-guided medical therapy
Study: 7642847
Drug: Ischemia-guided medical
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemia-guided medical therapy
Study: 2750268
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera B subunit-whole cell vaccine (BS-WC)
Study: 2750268
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole cell vaccine (WC)
Study: 2750268
Drug: Common antigens
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common antigens in vaccines and Vibrionaceae strains
Study: 28330592
Drug: twice-weekly deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice-weekly deep TMS (dTMS) continuation treatment for up to 12 weeks
Study: 10226398
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 50 mgs in divided doses with radiation (6000 cGy in six weeks)
Study: 2653876
Drug: Nifedipine (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (double dose)
Study: 2653876
Drug: Nifedipine (sublingual)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (sublingual)
Study: 27055521
Drug: GSK2586184 (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 (50-400 mg, oral, twice daily for 12 weeks)
Study: 27055521
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, twice daily for 12 weeks)
Study: 18474451
Drug: Effleurage massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effleurage massage therapy (20 min of effleurage on ten occasions)
Study: 15598944
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2) every 3 weeks (Dq3w)
Study: 15598944
Drug: docetaxel 40
Normalized name: docetaxel 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 40 mg/m(2) given weekly for 6 weeks followed by 2 weeks of rest (Dqw)
Study: 7866080
Drug: Homoeopathic medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homoeopathic medicines
Study: 2680794
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg orally
Study: 25982539
Drug: Secukinumab retreatment
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab retreatment as needed (300 mg)
Study: 25982539
Drug: Secukinumab retreatment
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab retreatment as needed (150 mg)
Study: 25982539
Drug: Secukinumab fixed
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab fixed interval (300 mg)
Study: 25982539
Drug: Secukinumab fixed
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab fixed interval (150 mg)
Study: 23551359
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 μg two inhalations twice daily via Turbuhaler®
Study: 23551359
Drug: Formoterol 4.5
Normalized name: BUDESONIDE 80/FORMOTEROL 4.5MCG 60D INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 4.5 μg two inhalations twice daily via Turbuhaler®
Study: 8118901
Drug: Nonsurgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical therapy
Study: 17633357
Drug: Sequential Colon
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Colon Dialysis (SCD)
Study: 9515561
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg bolus over 5 minutes followed by continuous i.v. infusion of 50 microg/kg/min over 75 minutes)
Study: 24326967
Drug: Deep sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sclerectomy with mitomycin C 0.2 mg/mL
Study: 24326967
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C 0.2 mg/mL
Study: 16444435
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day, for 12 weeks)
Study: 12859311
Drug: Levobupivacaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 1.5 mg/ml, 10 ml/h (n = 26)
Study: 12859311
Drug: Levobupivacaine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 5 mg/ml, 3 ml/h (n = 33)
Study: 12859311
Drug: Levobupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 7.5 mg/ml, 2 ml/h (n = 31)
Study: 3900393
Drug: Diflunisal high
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal high dose (1000 mg daily)
Study: 3900393
Drug: Diflunisal low
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal low dose (750 mg daily)
Study: 3900393
Drug: Diflunisal (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (both doses)
Study: 3900393
Drug: Diflunisal high
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal high dose vs low dose
Study: 30615231
Drug: Metformin 1g
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1g
Study: 27480654
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine 10 ml (Group A)
Study: 27480654
Drug: 0.25% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% ropivacaine 20 ml (Group B)
Study: 25766415
Drug: Everolimus (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (5-10 mg/day)
Study: 17879544
Drug: Zhongfu Hypotension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhongfu Hypotension Capsule (ZHC) - 3 capsules (0.5 g/capsule) twice a day for 4 weeks
Study: 17879544
Drug: Lotensin Tablet
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lotensin Tablet - 1 tablet (10 mg/tab.) once a day for 4 weeks
Study: 15730353
Drug: Active medications
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medications (specific medications not detailed)
Study: 15730353
Drug: Active medications
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medications and Placebo
Study: 12142119
Drug: HERG K897T
Approvals — FDA: no, EMA: no, PMDA: no
Description: HERG K897T polymorphism (genotypes AC or CC)
Study: 375433
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and penicillin (60 mg/m2/8 h)
Study: 375433
Drug: Gentamicin (constant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (constant vs intermittent infusion)
Study: 25485782
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2/3 h), carboplatin (AUC 5), and bevacizumab (15 mg/kg) administered every 21 days for 6-8 cycles, followed by maintenance therapy with bevacizumab (15 mg/kg) every 21 days for 16 cycles.
Study: 25485782
Drug: Paclitaxel, carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, carboplatin, and bevacizumab combination therapy.
Study: 17318618
Drug: Ibuprofen (5%)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (5%)
Study: 17318618
Drug: Arnica (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica (50 g tincture/100 g, DER 1:20)
Study: 11252073
Drug: Creatine (CR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (CR; 20 g.d‐1, 5 d)
Study: 16709303
Drug: budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol 160/4.5 microg, one inhalation, once or twice daily maintenance plus additional doses as needed (1 x SMART or 2 x SMART)
Study: 16709303
Drug: budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol 160/4.5 microg two inhalations twice daily plus formoterol 4.5 microg as needed (2 x 2 FIX + F)
Study: 7877117
Drug: Trimipramine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine with adjunct sleep deprivation (SD)
Study: 7877117
Drug: Trimipramine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine with adjunct bright light (BL)
Study: 3182456
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg x 2 daily)
Study: 3182456
Drug: Pivampicillin (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (700 mg x 3 daily)
Study: 27869354
Drug: Olopatadine hydrochloride
Normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride 0.1% twice a day
Study: 27869354
Drug: Emedastine difumarate
Normalized name: Emedastine Difumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine difumarate 0.05% twice a day
Study: 23140547
Drug: Ranolazine 375
Normalized name: Ranolazine 375 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge
Study: 19886513
Drug: Weekly folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly folic acid (5,000 or 2,800 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Study: 19886513
Drug: Daily folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily folic acid (400 or 200 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Study: 9217033
Drug: Letrozole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.5 mg per day
Study: 9217033
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg per day
Study: 3064085
Drug: ZK 93426
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 93426 (benzodiazepine receptor antagonist with weak inverse agonist properties)
Study: 29637820
Drug: hUCB‐MSC infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: hUCB‐MSC infusion (4 infusions at a fixed dose of 5 × 10^7) with basic rehabilitation
Study: 29637820
Drug: hUCB‐MSC infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: hUCB‐MSC infusion
Study: 25641606
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg/day for 14 days coadministered with aspirin 150 mg/day for 6 days
Study: 25641606
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg/day for 14 days with maintenance warfarin (1-10 mg)
Study: 18416081
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus shenqi fuzheng injection
Study: 16858933
Drug: Bedtime calcium
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime calcium supplementation (2 calcium carbonate tablets, 334 mg per tablet)
Study: 12032788
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg loading dose of aminophylline
Study: 12032788
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg loading dose of aminophylline
Study: 8529534
Drug: Oral nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalmefene glucuronide
Study: 2905636
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketorolac tromethamine
Study: 2227078
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac tromethamine
Study: 150487
Drug: Levamisole (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (continuous administration for 16 weeks)
Study: 12207836
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg twice/d) and Vitamin E (100 mg twice/d) for 12 weeks
Study: 26790705
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 µg/kg for five days)
Study: 24886264
Drug: Proactive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone peer support (two calls within the first ten days postpartum, then weekly calls until week twelve, with continued contact until six months postpartum)
Study: 20973465
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (Sprinkles) - 60 sachets (12.5 mg elemental iron) taken daily for 2 months
Study: 12534637
Drug: Aminophylline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (mean rate 9.2 +/- 2.6 micro g kg‐1 min‐1)
Study: 24894386
Drug: Levosimendan (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.05 to 0.2 μg.kg⁻¹.min⁻¹ for 24 hours)
Study: 21194606
Drug: 300-mg test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg test formulation of rifampicin
Study: 21194606
Drug: 150-mg reference
Normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150-mg reference formulation of rifampicin
Study: 21194606
Drug: 300-mg test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg test formulation of 25-desacetyl rifampicin